Monday's Conference Call Kicks Off the Afrezza Approval Run-Up
Expect an update on the the Afrezza trials that are expected to be completed in April. Also the company has two partnerships for development of its cancer drugs that could generate over $300,000,000 plus royalties to the company.
Take the time to listen to the conference call. It may entice you to add a few shares for the Afrezza approval run.
200-300% upside by the end of the year is quite possible.
Total BS. There will be nothing new other than MNKD telling us that September FDA submit will more likely will be in the 4th q which will be in December the earliest. There is no upside as more dilution is ahead and FDA approval wont happen till MID 2014.